SOL Capital Management CO Trims Stake in iShares Biotechnology ETF (NASDAQ:IBB)

SOL Capital Management CO lowered its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 9.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,955 shares of the financial services provider’s stock after selling 3,210 shares during the period. SOL Capital Management CO owned approximately 0.07% of iShares Biotechnology ETF worth $4,225,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. SPC Financial Inc. lifted its stake in iShares Biotechnology ETF by 2.4% in the third quarter. SPC Financial Inc. now owns 3,265 shares of the financial services provider’s stock worth $475,000 after purchasing an additional 75 shares during the last quarter. Werba Rubin Papier Wealth Management increased its position in iShares Biotechnology ETF by 2.7% during the 3rd quarter. Werba Rubin Papier Wealth Management now owns 2,918 shares of the financial services provider’s stock valued at $425,000 after purchasing an additional 76 shares during the period. Capital Investment Advisors LLC boosted its stake in shares of iShares Biotechnology ETF by 1.0% during the 4th quarter. Capital Investment Advisors LLC now owns 10,449 shares of the financial services provider’s stock valued at $1,381,000 after purchasing an additional 99 shares in the last quarter. Magnus Financial Group LLC increased its position in shares of iShares Biotechnology ETF by 0.8% during the fourth quarter. Magnus Financial Group LLC now owns 12,967 shares of the financial services provider’s stock valued at $1,714,000 after buying an additional 104 shares during the period. Finally, Daiwa Securities Group Inc. raised its stake in iShares Biotechnology ETF by 12.0% in the third quarter. Daiwa Securities Group Inc. now owns 1,028 shares of the financial services provider’s stock worth $150,000 after buying an additional 110 shares in the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

NASDAQ IBB opened at $138.87 on Friday. The stock’s 50 day moving average is $136.35 and its 200 day moving average is $141.67. iShares Biotechnology ETF has a twelve month low of $123.60 and a twelve month high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The firm also recently disclosed a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were given a dividend of $0.0624 per share. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.